Literature DB >> 24951472

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.

YongKu Ryu1, Connor P Hall2, C Patrick Reynolds3, Min H Kang4.   

Abstract

ABT-737 is a BH3-mimetic that has a wide spectrum of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts. Previously, we reported that in response to ABT-737, ABT-737-resistant ALL cell lines showed an apparent increase in Mcl-1 (an anti-apoptotic Bcl-2 family protein that is not effectively inhibited by ABT-737) while ABT-737-sensitive ALL cell lines showed decreased Mcl-1 levels. Here we explored the mechanism of Mcl-1 cleavage by ABT-737 and the effect of adjacent phosphorylation sites on Mcl-1 cleavage and apoptosis induced by ABT-737 in a human B-lineage ALL cell line. Caspase cleavage sites in Mcl-1 and the effect of mutation in Mcl-1 phosphorylation sites were determined by transducing Mcl-1 variants tagged with the V5 epitope into human ALL cells. Cytotoxicity was by fluorescence-based DIMSCAN, and changes in protein by immunoblotting. ABT-737 induced a caspase-dependent cleavage of Mcl-1. Of the two Mcl-1 caspase cleavage sites (D127 and D157), D157 was the site of ABT-737-induced cleavage in ALL cells. Cells with exogenously expressed Mcl-1 Δ157 fragment showed greater caspase-3 and caspase-9 activation when they were treated with ABT-737 compared with cells expressing wild-type or D157A mutant Mcl-1. Cells with mutated phosphorylation sites on Mcl-1 (S159A and T163A) were less susceptible to Mcl-1 cleavage and apoptosis induced by ABT-737. Our data showed that Mcl-1 is post-translationally regulated in response to ABT-737 treatment, primarily via a caspase-dependent cleavage that generates a pro-apoptotic Mcl-1 fragment.
© 2014 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  ABT-737; Mcl-1; acute lymphoblastic leukemia; caspase-dependent cleavage

Mesh:

Substances:

Year:  2014        PMID: 24951472     DOI: 10.1177/1535370214538745

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  3 in total

1.  Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.

Authors:  Jennifer M Pearson; Su-Fern Tan; Arati Sharma; Charyguly Annageldiyev; Todd E Fox; Jose Luis Abad; Gemma Fabrias; Dhimant Desai; Shantu Amin; Hong-Gang Wang; Myles C Cabot; David F Claxton; Mark Kester; David J Feith; Thomas P Loughran
Journal:  Mol Cancer Res       Date:  2019-11-19       Impact factor: 5.852

2.  Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Authors:  Stefano Iacovelli; Maria Rosaria Ricciardi; Matteo Allegretti; Simone Mirabilii; Roberto Licchetta; Paola Bergamo; Cinzia Rinaldo; Ann Zeuner; Robin Foà; Michele Milella; James A McCubrey; Alberto M Martelli; Agostino Tafuri
Journal:  Oncotarget       Date:  2015-10-13

Review 3.  Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

Authors:  S Baig; I Seevasant; J Mohamad; A Mukheem; H Z Huri; T Kamarul
Journal:  Cell Death Dis       Date:  2016-01-14       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.